These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36598389)

  • 1. The Role of Insulin-like Growth Factor-1 and Its Receptor in the Eye: A Review and Implications for IGF-1R Inhibition.
    Truong T; Silkiss RZ
    Ophthalmic Plast Reconstr Surg; 2023 Jan-Feb 01; 39(1):4-12. PubMed ID: 36598389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms in Graves Eye Disease: Apoptosis as the End Point of Insulin-Like Growth Factor 1 Receptor Inhibition.
    Morshed SA; Ma R; Latif R; Davies TF
    Thyroid; 2022 Apr; 32(4):429-439. PubMed ID: 34927457
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical Management and Therapeutic Strategies for the Thyroid-Associated Ophthalmopathy: Current and Future Perspectives.
    Mishra S; Maurya VK; Kumar S; Ankita ; Kaur A; Saxena SK
    Curr Eye Res; 2020 Nov; 45(11):1325-1341. PubMed ID: 32567373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Teprotumumab (Tepezza): from the discovery and development of medicines to USFDA approval for active thyroid eye disease (TED) treatment.
    Ali F; Chorsiya A; Anjum V; Ali A
    Int Ophthalmol; 2021 Apr; 41(4):1549-1561. PubMed ID: 33481154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves' orbitopathy.
    Smith TJ; Hegedüs L; Douglas RS
    Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):291-302. PubMed ID: 22632366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thyroid Eye Disease, Teprotumumab, and Hearing Loss: An Evolving Role for Otolaryngologists.
    Chern A; Dagi Glass LR; Gudis DA
    Otolaryngol Head Neck Surg; 2021 Dec; 165(6):757-758. PubMed ID: 33781112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy.
    Marinò M; Rotondo Dottore G; Ionni I; Lanzolla G; Sabini E; Ricci D; Sframeli A; Mazzi B; Menconi F; Latrofa F; Vitti P; Marcocci C; Chiovato L
    J Endocrinol Invest; 2019 Apr; 42(4):471-480. PubMed ID: 30132285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression.
    Ugradar S; Shi L; Wang Y; Mester T; Yang H; Douglas RS
    Eye (Lond); 2021 Sep; 35(9):2607-2612. PubMed ID: 33221815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future Projections in Thyroid Eye Disease.
    Barbesino G; Salvi M; Freitag SK
    J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S47-S56. PubMed ID: 36346684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease.
    Gulbins A; Horstmann M; Daser A; Flögel U; Oeverhaus M; Bechrakis NE; Banga JP; Keitsch S; Wilker B; Krause G; Hammer GD; Spencer AG; Zeidan R; Eckstein A; Philipp S; Görtz GE
    Front Endocrinol (Lausanne); 2023; 14():1211473. PubMed ID: 37435490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Teprotumumab: First Approval.
    Markham A
    Drugs; 2020 Apr; 80(5):509-512. PubMed ID: 32157641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin-Like Growth Factor Pathway and the Thyroid.
    Smith TJ
    Front Endocrinol (Lausanne); 2021; 12():653627. PubMed ID: 34149612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TSH-Mediated TNFα Production in Human Fibrocytes Is Inhibited by Teprotumumab, an IGF-1R Antagonist.
    Chen H; Shan SJ; Mester T; Wei YH; Douglas RS
    PLoS One; 2015; 10(6):e0130322. PubMed ID: 26087256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease.
    Kossler AL; Douglas R; Dosiou C
    J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S36-S46. PubMed ID: 36346685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A New Era in the Treatment of Thyroid Eye Disease.
    Patel A; Yang H; Douglas RS
    Am J Ophthalmol; 2019 Dec; 208():281-288. PubMed ID: 31377284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting TSH and IGF-1 Receptors to Treat Thyroid Eye Disease.
    Neumann S; Krieger CC; Gershengorn MC
    Eur Thyroid J; 2020 Dec; 9(Suppl 1):59-65. PubMed ID: 33511086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Teprotumumab: A Review in Thyroid Eye Disease.
    Nie T; Lamb YN
    Drugs; 2022 Nov; 82(17):1663-1670. PubMed ID: 36418673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes.
    Chen H; Mester T; Raychaudhuri N; Kauh CY; Gupta S; Smith TJ; Douglas RS
    J Clin Endocrinol Metab; 2014 Sep; 99(9):E1635-40. PubMed ID: 24878056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin-like growth factor 1 promotes the proliferation and adipogenesis of orbital adipose-derived stromal cells in thyroid-associated ophthalmopathy.
    Zhao P; Deng Y; Gu P; Wang Y; Zhou H; Hu Y; Chen P; Fan X
    Exp Eye Res; 2013 Feb; 107():65-73. PubMed ID: 23219871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of teprotumumab therapy in patients with long-duration thyroid eye disease.
    Subramanian PS; Cho RI; Kahana A
    Curr Opin Ophthalmol; 2023 Nov; 34(6):487-492. PubMed ID: 37610428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.